Neu-Laxova syndrome

Neu–Laxova syndrome
Classification and external resources
Specialty medical genetics
ICD-10 Q87.8
ICD-9-CM 759.89
OMIM 256520 616038

Neu–Laxova syndrome (also known as Neu syndrome or Neu-Povysilová syndrome, abbreviated as NLS) is a rare autosomal recessive disorder characterized by severe intrauterine growth restriction and multiple congenital malformations. Neu–Laxova syndrome is a very severe disorder, leading to stillbirth or neonatal death. It was first described by Dr. Richard Neu in 1971[1] and Dr. Renata Laxova in 1972[2] as a lethal disorder in siblings with multiple malformations. Neu–Laxova syndrome is an extremely rare disorder with less than 100 cases reported in medical literature.

Phenotype

Neu-Laxova syndrome presents with severe malformations leading to prenatal or neonatal death. Typically, NLS involves characteristic facial features, decreased fetal movements and skin abnormalities.[3] Fetuses or newborns with Neu–Laxova syndrome have typical facial characteristics which include proptosis (bulging eyes) with eyelid malformations, nose malformations, round and gaping mouth, micrognathia (small jaw) and low set or malformed ears. Additional facial malformations may be present, such as cleft lip or cleft palate. Limb malformations are common and involve the fingers (syndactyly), hands or feet. Additionally, edema and flexion deformities are often present. Other features of NLS are severe intrauterine growth restriction, skin abnormalities (ichthyosis and hyperkeratosis) and decreased movement. Malformations in the central nervous system are frequent and may include microcephaly, lissencephaly or microgyria, hypoplasia of the cerebellum and agenesis of the corpus callosum. Other malformations may also be present, such as neural tube defects.

Causes

Neu-Laxova syndrome is a heterogeneous metabolic disorder caused by homozygous or compound heterozygous mutations in the PHGDH, PSAT1 and PSPH genes.[4][5] These genes are involved in the serine biosynthesis pathway and are essential for cell proliferation. Mutations in all three genes had been previously identified as the cause of serine-deficiency syndromes. Although there is some clinical overlap between NLS and these neurometabolic disorders, the phenotype in other serine-deficiency disorders is milder.

Diagnosis

The diagnosis is usually based on clinical features present at birth. Ultrasound in the second trimester may show abnormalities associates with NLS, including polyhydramnios, intrauterine growth restriction, microcephaly, proptosis and decreased fetal motility.

Prognosis

The prognosis is poor; affected individuals are either stillborn or die shortly after birth. The longest survival reported in literature is of 134 days. This syndrome is transmitted as an autosomal recessive disorder and there is a risk for recurrence of 25% in future pregnancies.

References

  1. ↑ Neu, Richard L.; Kajii, Tadashi; Gardner, Lytt I.; Nagyfy, Stephen F.; King, Saddie (March 1, 1971). "A Lethal Syndrome of Microcephaly with Multiple Congenital Anomalies in Three Siblings". Pediatrics. 47 (3): 610–612.
  2. ↑ Laxova, Renata; Ohara, P.T.; Timothy, J.A.D. (March 1972). "A further example of a lethal autosomal recessive condition in sibs". Journal of Intellectual Disability Research. 16 (1-2): 139–143. doi:10.1111/j.1365-2788.1972.tb01585.x.
  3. ↑ Manning, Melanie; Cunniff, Christopher M; Colby, Christopher E; Yasser, Y El-Sayed; Hoyme, H Eugene (March 2004). "Neu–Laxova syndrome: Detailed prenatal diagnostic and post-mortem findings and literature review". American Journal of Medical Genetics Part A. 125A (3): 240–249. doi:10.1002/ajmg.a.20467.
  4. ↑ Shaheen, Ranad; Rahbeeni Zuhair, Alhashem Amal, Faqeih Eissa, Zhao Qi, Xiong Yong, Almoisheer Agaadir, Al-Qattan Sarah M., Almadani Halima A., Al-Onazi Noufa, Al-Baqawi Badi S., Saleh Mohammad Ali, Alkuraya Fowzan S. (June 2014). "Neu-Laxova Syndrome, an Inborn Error of Serine Metabolism, Is Caused by Mutations in PHGDH". American Journal of Human Genetics. 94 (6): 898–904. doi:10.1016/j.ajhg.2014.04.015. PMC 4121479Freely accessible. PMID 24836451. Cite uses deprecated parameter |coauthors= (help)
  5. ↑ Acuna-Hidalgo, Rocio; Schanze D, Kariminejad A, Nordgren A, Kariminejad MH, Conner P, Grigelioniene G, Nilsson D, Nordenskjöld M, Wedell A, Freyer C, Wredenberg A, Wieczorek D, Gillessen-Kaesbach G, Kayserili H, Elcioglu N, Ghaderi-Sohi S, Goodarzi P, Setayesh H, van de Vorst M, Steehouwer M, Pfundt R, Krabichler B, Curry C, MacKenzie MG, Boycott KM, Gilissen C, Janecke AR, Hoischen A, Zenker M. (September 2014). "Neu-Laxova Syndrome Is a Heterogeneous Metabolic Disorder Caused by Defects in Enzymes of the L-Serine Biosynthesis Pathway". American Journal of Human Genetics. 95 (3): 285–293. doi:10.1016/j.ajhg.2014.07.012. PMC 4157144Freely accessible. PMID 25152457. Cite uses deprecated parameter |coauthors= (help)
This article is issued from Wikipedia - version of the 5/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.